Is Orgenesis, Inc. overvalued or undervalued?

As of 9 February 2024, the valuation grade for Orgenesis, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued given its negative financial metrics, including a price-to-book value of -0.42 and an EV to EBITDA ratio of -1.01. Furthermore, the EV to Sales ratio stands at 24.38, which is excessively high compared to industry norms.
In comparison with peers, Orgenesis, Inc. shows a stark contrast to Catalyst Biosciences, Inc., which is deemed expensive with a P/E ratio of 90.02, while other peers like Forte Biosciences, Inc. and Senti Biosciences, Inc. also do not qualify with negative valuation metrics. The company's recent stock performance has been dismal, with a 1-year return of -71.41%, significantly underperforming the S&P 500's 10.26% return in the same period. Overall, Orgenesis, Inc. is overvalued based on its current financial ratios and peer comparisons.